(Reuters) – The U.S. government’s Medicare health insurance program can begin negotiating prices for some prescription drugs this fall under a new program, a federal judge ruled on Friday, vindicating one of President Joe Biden’s signature initiatives.
The order by U.S. District Judge Michael Newman in Dayton, Ohio, comes in a lawsuit brought against the Biden administration by the U.S. Chamber of Commerce. The nation’s largest business lobbying group had argued the program would give federal regulators too much power to set drug prices and would stifle innovation.
(Reporting By Brendan Pierson in New York and Nate Raymond in Boston; additional reporting by Costas Pitas; Editing by Alexia Garamfalvi and Bill Berkrot)
Brought to you by www.srnnews.com
